155 related articles for article (PubMed ID: 35940437)
1. Anti-inflammatory effects of siponimod on astrocytes.
Ogasawara A; Takeuchi H; Komiya H; Ogawa Y; Nishimura K; Kubota S; Hashiguchi S; Takahashi K; Kunii M; Tanaka K; Tada M; Doi H; Tanaka F
Neurosci Res; 2022 Nov; 184():38-46. PubMed ID: 35940437
[TBL] [Abstract][Full Text] [Related]
2. Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration.
Colombo E; Bassani C; De Angelis A; Ruffini F; Ottoboni L; Comi G; Martino G; Farina C
Front Immunol; 2020; 11():635. PubMed ID: 32322257
[TBL] [Abstract][Full Text] [Related]
3. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
Gurrea-Rubio M; Wang Q; Mills EA; Wu Q; Pitt D; Tsou PS; Fox DA; Mao-Draayer Y
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473703
[TBL] [Abstract][Full Text] [Related]
4. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function.
Spampinato SF; Merlo S; Sano Y; Kanda T; Sortino MA
Biochem Pharmacol; 2021 Apr; 186():114465. PubMed ID: 33577891
[TBL] [Abstract][Full Text] [Related]
6. Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights.
Bigaud M; Rudolph B; Briard E; Beerli C; Hofmann A; Hermes E; Muellershausen F; Schubart A; Gardin A
Mult Scler J Exp Transl Clin; 2021 Oct; 7(4):20552173211049168. PubMed ID: 34777855
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
Gajofatto A
Drug Des Devel Ther; 2017; 11():3153-3157. PubMed ID: 29138536
[TBL] [Abstract][Full Text] [Related]
8. Siponimod in the treatment of multiple sclerosis.
Goodman AD; Anadani N; Gerwitz L
Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
[No Abstract] [Full Text] [Related]
9. Does Siponimod Exert Direct Effects in the Central Nervous System?
Kipp M
Cells; 2020 Jul; 9(8):. PubMed ID: 32722245
[TBL] [Abstract][Full Text] [Related]
10. Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5.
Behrangi N; Heinig L; Frintrop L; Santrau E; Kurth J; Krause B; Atanasova D; Clarner T; Fragoulis A; Joksch M; Rudolf H; Meuth SG; Joost S; Kipp M
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2204509119. PubMed ID: 36161894
[TBL] [Abstract][Full Text] [Related]
11. Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
Uosef A; Vaughn N; Chu X; Elshawwaf M; Abdelshafy AAA; Elsaid KMK; Ghobrial RM; Kloc M
Arch Immunol Ther Exp (Warsz); 2020 Jun; 68(3):19. PubMed ID: 32488676
[TBL] [Abstract][Full Text] [Related]
12. Siponimod to treat secondary progressive multiple sclerosis.
Gajofatto A; Turatti M
Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
[TBL] [Abstract][Full Text] [Related]
13. Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation.
Gruchot J; Lein F; Lewen I; Reiche L; Weyers V; Petzsch P; Göttle P; Köhrer K; Hartung HP; Küry P; Kremer D
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362063
[TBL] [Abstract][Full Text] [Related]
14. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G
Front Immunol; 2024; 15():1416133. PubMed ID: 38911847
[TBL] [Abstract][Full Text] [Related]
15. Microglia Contributes to BAF-312 Effects on Blood-Brain Barrier Stability.
Spampinato SF; Costantino G; Merlo S; Canonico PL; Sortino MA
Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139013
[TBL] [Abstract][Full Text] [Related]
16. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.
O'Sullivan C; Schubart A; Mir AK; Dev KK
J Neuroinflammation; 2016 Feb; 13():31. PubMed ID: 26856814
[TBL] [Abstract][Full Text] [Related]
17. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
[TBL] [Abstract][Full Text] [Related]
18. Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
Weier A; Enders M; Kirchner P; Ekici A; Bigaud M; Kapitza C; Wörl J; Kuerten S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430692
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory Effects of Siponimod in a Mouse Model of Excitotoxicity-Induced Retinal Injury.
Basavarajappa D; Gupta V; Chitranshi N; Viswanathan D; Gupta V; Vander Wall R; Palanivel V; Mirzaei M; You Y; Klistorner A; Graham SL
Mol Neurobiol; 2023 Dec; 60(12):7222-7237. PubMed ID: 37542647
[TBL] [Abstract][Full Text] [Related]
20. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
